A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia
Latest Information Update: 18 Jan 2022
At a glance
- Drugs Daunorubicin liposomal (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacodynamics; Proof of concept
- 12 Jan 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 21 Jun 2019 Status changed from recruiting to active, no longer recruiting.